BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35739016)

  • 41. SCLC-State of the Art and What Does the Future Have in Store?
    Kahnert K; Kauffmann-Guerrero D; Huber RM
    Clin Lung Cancer; 2016 Sep; 17(5):325-333. PubMed ID: 27397481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
    Walls M; Baxi SM; Mehta PP; Liu KK; Zhu J; Estrella H; Li C; Zientek M; Zong Q; Smeal T; Yin MJ
    Clin Cancer Res; 2014 Feb; 20(3):631-43. PubMed ID: 24240111
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer.
    Lei L; Jiang ZM; Li CH; Lu HY
    Curr Med Sci; 2019 Jun; 39(3):379-384. PubMed ID: 31209806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.
    Bordi P; Tiseo M; Barbieri F; Bavieri M; Sartori G; Marchetti A; Buttitta F; Bortesi B; Ambrosini-Spaltro A; Gnetti L; Silini EM; Ardizzoni A; Rossi G
    Lung Cancer; 2014 Dec; 86(3):324-8. PubMed ID: 25453846
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A role for IGF-1R-targeted therapies in small-cell lung cancer?
    Gately K; Collins I; Forde L; Al-Alao B; Young V; Gerg M; Feuerhake F; O'Byrne K
    Clin Lung Cancer; 2011 Jan; 12(1):38-42. PubMed ID: 21273178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Su Z; Wang Z; Ni X; Duan J; Gao Y; Zhuo M; Li R; Zhao J; Ma Q; Bai H; Chen H; Wang S; Chen X; An T; Wang Y; Tian Y; Yu J; Wang D; Xie XS; Bai F; Wang J
    Clin Cancer Res; 2019 Aug; 25(16):5049-5060. PubMed ID: 31113842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
    Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
    Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
    Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
    Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surgery for limited-stage small-cell lung cancer.
    Barnes H; See K; Barnett S; Manser R
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011917. PubMed ID: 28429473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.
    Schaffer BE; Park KS; Yiu G; Conklin JF; Lin C; Burkhart DL; Karnezis AN; Sweet-Cordero EA; Sage J
    Cancer Res; 2010 May; 70(10):3877-83. PubMed ID: 20406986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 54. Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    Muppa P; Parrilha Terra SBS; Sharma A; Mansfield AS; Aubry MC; Bhinge K; Asiedu MK; de Andrade M; Janaki N; Murphy SJ; Nasir A; Van Keulen V; Vasmatzis G; Wigle DA; Yang P; Yi ES; Peikert T; Kosari F
    J Thorac Oncol; 2019 Jul; 14(7):1286-1295. PubMed ID: 31078775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic impact of a 3-MicroRNA signature in cytological samples of small cell lung cancer.
    Mancuso G; Bovio E; Rena O; Rrapaj E; Mercalli F; Veggiani C; Paganotti A; Andorno S; Boldorini R
    Cancer Cytopathol; 2016 Sep; 124(9):621-9. PubMed ID: 27153322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.
    Vollbrecht C; Werner R; Walter RF; Christoph DC; Heukamp LC; Peifer M; Hirsch B; Burbat L; Mairinger T; Schmid KW; Wohlschlaeger J; Mairinger FD
    Br J Cancer; 2015 Dec; 113(12):1704-11. PubMed ID: 26645239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features.
    Jin W; Lei Z; Xu S; Fachen Z; Yixiang Z; Shilei Z; Tao G; Zhe S; Fengzhou L; Su WH; Chundong G
    Biomed Res Int; 2021; 2021():3609028. PubMed ID: 33880365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
    Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.